Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double Masked, Active Treatment-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne) Photodynamic Therapy in Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration
Brief Summary: This is a phase III, multicenter, randomized, double-masked, active treatment-controlled study of intravitreally administered ranibizumab compared with verteporfin (Visudyne) photodynamic therapy (PDT) in treating subfoveal neovascular mascular degeneration.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4
B: Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A
C: Arm Label: ranibizumab 0.5mg Q4; Type: ACTIVE_COMPARATOR; Interventions: Biological: ranibizumab | Arm Label: aflibercept injection 2.0mg Q4; Type: EXPERIMENTAL; Interventions: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321) | Arm Label: aflibercept injection 0.5mg Q4; Type: EXPERIMENTAL; Interventions: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321) | Arm Label: aflibercept injection 2.0mg Q8; Type: EXPERIMENTAL; Interventions: Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321) | Intervention Type: BIOLOGICAL; Name: ranibizumab; Assigned to Arm(s): ranibizumab 0.5mg Q4 | Intervention Type: BIOLOGICAL; Name: aflibercept injection (VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): aflibercept injection 2.0mg Q4 | Intervention Type: BIOLOGICAL; Name: aflibercept injection (VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): aflibercept injection 0.5mg Q4 | Intervention Type: BIOLOGICAL; Name: aflibercept injection (VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): aflibercept injection 2.0mg Q8
D: Arm Label: Ranibizumab 0.5mg Q4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Arm Label: Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4; Type: EXPERIMENTAL; Interventions: Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Arm Label: Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4; Type: EXPERIMENTAL; Interventions: Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Arm Label: Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8; Type: EXPERIMENTAL; Interventions: Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab 0.5mg Q4 | Intervention Type: BIOLOGICAL; Name: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 | Intervention Type: BIOLOGICAL; Name: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Intervention Type: BIOLOGICAL; Name: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321); Assigned to Arm(s): Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8

Answer: B